Bangladesh Leads Least Developed Country Call For IP Waiver
This article was originally published in PharmAsia News
Mammoth price differentials between patented and locally produced drugs in a country where nearly 25 million people live in extreme poverty are some of the justifications emerging from Bangladesh's promising pharmaceutical industry as the country led Least Developed Country (LDCs) members of the World Trade Organization (WTO) to seek an extension of the transitional period to enforce intellectual property rights on medicines.
You may also be interested in...
FDA action awaits Sun’s manufacturing facility in Halol after it failed to adequately address GMP deviations, though India’s top-ranked drug firm appears to have effectively lowered its dependence on the site that has had a patchy compliance run.
Pharmaceutical manufacturing in India is facing some early stress amid the new 21-day lock-down but both the industry and government machinery are actively engaged and working together to ensure that disruptions are minimized in the ‘pharmacy of the world.’
India has prohibited exports of hydroxychloroquine, though with concessions in specific instances, days after a national task force recommended the drug for the prophylaxis of SARS-CoV-2 infections. Home market supplies of the drug also appear strained for now.